3:41 PM
 | 
Feb 21, 2017
 |  BC Extra  |  Company News

Amphastar falls on CRL for intranasal naloxone

Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH) dropped $4.20 (23%) to $14.20 on Tuesday after it said it received a complete response letter from FDA for Naloxone Hydrochloride 2mg/0.5mL Nasal Spray, under review for the emergency treatment of known or suspected opioid...

Read the full 180 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >